Borui Xinchuang Biomedical Technology (Wuxi) Co., Ltd

Primary objective: Compared with telportin injection, to preliminarily evaluate the effectiveness of BGM0504 injection for weight control in non-diabetic moderate to severe obese subjects (BMI>35.0 kg/m2). Secondary objective: Compared with telportin injection, to evaluate the safety and tolerability of BGM0504 injection in non-diabetic moderate to severe obese subjects (BMI>35.0 kg/m2).

Primary objective: Compared with placebo, to evaluate the clinical efficacy of BGM0504 injection monotherapy for 32 weeks in Chinese patients with type 2 diabetes who have poor glycemic control after diet and exercise. Secondary objective: Compared with placebo, to evaluate the clinical efficacy of BGM0504 injection monotherapy for 52 weeks in Chinese patients with type 2 diabetes who have poor glycemic control after diet and exercise. Compared with placebo, to evaluate the clinical safety of BGM0504 injection monotherapy for 52 weeks in Chinese patients with type 2 diabetes who have poor glycemic control after diet and exercise.

Primary objective: Compared with semaglutide injection 1.0 mg, to evaluate the clinical efficacy of BGM0504 injection combined with metformin or metformin and sulfonylureas for 32 weeks in Chinese type 2 diabetes subjects with poor glycemic control after metformin alone or metformin and sulfonylureas. Secondary objective: Compared with semaglutide injection 1.0 mg, to evaluate the clinical efficacy of BGM0504 injection combined with metformin or metformin and sulfonylureas for 52 weeks in Chinese type 2 diabetes subjects with poor glycemic control after metformin alone or metformin and sulfonylureas. To evaluate the clinical safety of BGM0504 injection combined with metformin or metformin and sulfonylureas for 52 weeks compared with semaglutide injection 1.0 mg in Chinese patients with type 2 diabetes whose glycemic control was inadequately controlled by metformin alone or metformin and sulfonylureas.